<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101601398</journal-id>
<journal-id journal-id-type="pubmed-jr-id">42374</journal-id>
<journal-id journal-id-type="nlm-ta">Expert Opin Orphan Drugs</journal-id>
<journal-id journal-id-type="iso-abbrev">Expert Opin Orphan Drugs</journal-id>
<journal-title-group>
<journal-title>Expert opinion on orphan drugs</journal-title>
</journal-title-group>
<issn pub-type="epub">2167-8707</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28626620</article-id>
<article-id pub-id-type="pmc">5472383</article-id>
<article-id pub-id-type="doi">10.1080/21678707.2016.1244479</article-id>
<article-id pub-id-type="manuscript">NIHMS832287</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Tissue Chips to aid drug development and modeling for rare diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Low</surname>
<given-names>Lucie A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tagle</surname>
<given-names>Danilo A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>National Center for Advancing Translational Sciences, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD, 20892</aff>
<aff id="A2"><label>2</label>National Center for Complementary and Integrative Health, National Institutes of Health, 35 Convent Drive, Bethesda, MD, 20892</aff>
<author-notes>
<fn id="FN1">
<p id="P1">LAL: Tissue Chip Program Manager, <email>lucie.low@nih.gov</email>, 301 594 7609</p>
<p id="P2">DAT: Associate Director for Special Initiatives</p>
</fn>
<corresp id="CR1"><label>*</label>corresponding author <email>danilo.tagle@nih.gov</email>, 301 594 8064</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>19</day>
<month>10</month>
<year>2017</year>
</pub-date>
<volume>4</volume>
<issue>11</issue>
<fpage>1113</fpage>
<lpage>1121</lpage>
<!--elocation-id from pubmed: 10.1080/21678707.2016.1244479-->
<self-uri xlink:href="http://www.tandfonline.com/doi/abs/10.1080/21678707.2016.1244479"></self-uri>
<abstract>
<sec id="S1">
<title>Introduction</title>
<p id="P3">The technologies used to design, create and use microphysiological systems (MPS, “tissue chips” or “organs-on-chips”) have progressed rapidly in the last 5 years, and validation studies of the functional relevance of these platforms to human physiology, and response to drugs for individual model organ systems, are well underway. These studies are paving the way for integrated multi-organ systems that can model diseases and predict drug efficacy and toxicology of multiple organs in real-time, improving the potential for diagnostics and development of novel treatments of rare diseases in the future.</p>
</sec>
<sec id="S2">
<title>Areas covered</title>
<p id="P4">This review will briefly summarize the current state of tissue chip research and highlight model systems where these microfabricated (or bioengineered) devices are already being used to screen therapeutics, model disease states, and provide potential treatments in addition to helping elucidate the basic molecular and cellular phenotypes of rare diseases.</p>
</sec>
<sec id="S3">
<title>Expert opinion</title>
<p id="P5">Microphysiological systems hold great promise and potential for modeling rare disorders, as well as for their potential use to enhance the predictive power of new drug therapeutics, plus potentially increase the statistical power of clinical trials while removing the inherent risks of these trials in rare disease populations.</p>
</sec>
</abstract>
<kwd-group>
<kwd>clinical trials</kwd>
<kwd>drug development</kwd>
<kwd>induced pluripotent stem cells (iPSCs)</kwd>
<kwd>microphysiological systems/platforms</kwd>
<kwd>rare diseases</kwd>
<kwd>tissue chips</kwd>
<kwd>toxicity screening</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>